- Home
- TYRA vs ETNB Comparison
TYRA vs ETNB Comparison
Compare TYRA & ETNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TYRA
- ETNB
- Stock Information
- Founded
- TYRA 2018
- ETNB 2018
- Country
- TYRA United States
- ETNB United States
- Employees
- TYRA N/A
- ETNB N/A
- Industry
- TYRA Biotechnology: Pharmaceutical Preparations
- ETNB Biotechnology: Pharmaceutical Preparations
- Sector
- TYRA Health Care
- ETNB Health Care
- Exchange
- TYRA Nasdaq
- ETNB Nasdaq
- Market Cap
- TYRA 812.7M
- ETNB 867.4M
- IPO Year
- TYRA 2021
- ETNB 2019
- Fundamental
- Price
- TYRA $15.36
- ETNB $8.38
- Analyst Decision
- TYRA Strong Buy
- ETNB Buy
- Analyst Count
- TYRA 5
- ETNB 7
- Target Price
- TYRA $31.00
- ETNB $30.33
- AVG Volume (30 Days)
- TYRA 599.6K
- ETNB 999.8K
- Earning Date
- TYRA 11-07-2024
- ETNB 11-07-2024
- Dividend Yield
- TYRA N/A
- ETNB N/A
- EPS Growth
- TYRA N/A
- ETNB N/A
- EPS
- TYRA N/A
- ETNB N/A
- Revenue
- TYRA N/A
- ETNB N/A
- Revenue This Year
- TYRA N/A
- ETNB N/A
- Revenue Next Year
- TYRA N/A
- ETNB $133.30
- P/E Ratio
- TYRA N/A
- ETNB N/A
- Revenue Growth
- TYRA N/A
- ETNB N/A
- 52 Week Low
- TYRA $10.60
- ETNB $7.00
- 52 Week High
- TYRA $29.60
- ETNB $16.63
- Technical
- Relative Strength Index (RSI)
- TYRA 34.38
- ETNB 48.14
- Support Level
- TYRA $15.04
- ETNB $7.68
- Resistance Level
- TYRA $16.51
- ETNB $10.01
- Average True Range (ATR)
- TYRA 0.94
- ETNB 0.73
- MACD
- TYRA 0.04
- ETNB -0.17
- Stochastic Oscillator
- TYRA 11.68
- ETNB 23.15
About TYRA Tyra Biosciences Inc.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology The Company's in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNAPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. Its lead product candidate is TYRA 300, an FGFR3 selective inhibitor with an initial focus on patients with metastatic urothelial carcinoma of the bladder and urinary tract (mUC).
About ETNB 89bio Inc.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).